CN1711912A - Health-care food for delaying senility and regulating blood fat, and its production - Google Patents
Health-care food for delaying senility and regulating blood fat, and its production Download PDFInfo
- Publication number
- CN1711912A CN1711912A CNA2004100133423A CN200410013342A CN1711912A CN 1711912 A CN1711912 A CN 1711912A CN A2004100133423 A CNA2004100133423 A CN A2004100133423A CN 200410013342 A CN200410013342 A CN 200410013342A CN 1711912 A CN1711912 A CN 1711912A
- Authority
- CN
- China
- Prior art keywords
- parts
- lecithin
- health food
- slow down
- blood lipid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000004369 blood Anatomy 0.000 title claims abstract description 32
- 239000008280 blood Substances 0.000 title claims abstract description 32
- 238000004519 manufacturing process Methods 0.000 title claims description 22
- 235000013305 food Nutrition 0.000 title abstract description 6
- 230000001105 regulatory effect Effects 0.000 title abstract description 3
- 235000010445 lecithin Nutrition 0.000 claims abstract description 56
- 239000000787 lecithin Substances 0.000 claims abstract description 56
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims abstract description 48
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims abstract description 48
- 229940067606 lecithin Drugs 0.000 claims abstract description 47
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 claims abstract description 40
- 239000000843 powder Substances 0.000 claims abstract description 34
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims abstract description 32
- 235000019359 magnesium stearate Nutrition 0.000 claims abstract description 24
- 229910000019 calcium carbonate Inorganic materials 0.000 claims abstract description 20
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims abstract description 18
- 229930006000 Sucrose Natural products 0.000 claims abstract description 18
- 229960004793 sucrose Drugs 0.000 claims abstract description 18
- 239000000546 pharmaceutical excipient Substances 0.000 claims abstract description 13
- 239000000741 silica gel Substances 0.000 claims abstract description 12
- 229910002027 silica gel Inorganic materials 0.000 claims abstract description 12
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims abstract description 10
- 239000008101 lactose Substances 0.000 claims abstract description 10
- 108010010803 Gelatin Proteins 0.000 claims abstract description 9
- 239000008273 gelatin Substances 0.000 claims abstract description 9
- 229920000159 gelatin Polymers 0.000 claims abstract description 9
- 235000019322 gelatine Nutrition 0.000 claims abstract description 9
- 235000011852 gelatine desserts Nutrition 0.000 claims abstract description 9
- 239000001506 calcium phosphate Substances 0.000 claims abstract description 8
- 229910000389 calcium phosphate Inorganic materials 0.000 claims abstract description 8
- 235000011010 calcium phosphates Nutrition 0.000 claims abstract description 8
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 claims abstract description 8
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims abstract description 6
- 239000000600 sorbitol Substances 0.000 claims abstract description 6
- 235000013402 health food Nutrition 0.000 claims description 30
- 150000002632 lipids Chemical class 0.000 claims description 30
- 230000032683 aging Effects 0.000 claims description 25
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 22
- -1 fluidizer Substances 0.000 claims description 20
- 238000000576 coating method Methods 0.000 claims description 18
- 239000011248 coating agent Substances 0.000 claims description 17
- 239000000463 material Substances 0.000 claims description 14
- 239000008187 granular material Substances 0.000 claims description 13
- 239000002994 raw material Substances 0.000 claims description 12
- 229930003231 vitamin Natural products 0.000 claims description 12
- 239000011782 vitamin Substances 0.000 claims description 12
- 229940088594 vitamin Drugs 0.000 claims description 12
- 235000013343 vitamin Nutrition 0.000 claims description 12
- 150000003722 vitamin derivatives Chemical class 0.000 claims description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 12
- 229930003427 Vitamin E Natural products 0.000 claims description 11
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims description 11
- 239000000203 mixture Substances 0.000 claims description 11
- 235000019165 vitamin E Nutrition 0.000 claims description 11
- 229940046009 vitamin E Drugs 0.000 claims description 11
- 239000011709 vitamin E Substances 0.000 claims description 11
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 claims description 10
- 239000000499 gel Substances 0.000 claims description 10
- 239000000377 silicon dioxide Substances 0.000 claims description 10
- 229940083466 soybean lecithin Drugs 0.000 claims description 10
- 239000007779 soft material Substances 0.000 claims description 9
- 239000011230 binding agent Substances 0.000 claims description 6
- 229960003563 calcium carbonate Drugs 0.000 claims description 6
- 235000010216 calcium carbonate Nutrition 0.000 claims description 6
- 239000000945 filler Substances 0.000 claims description 6
- 239000000314 lubricant Substances 0.000 claims description 5
- 150000003904 phospholipids Chemical class 0.000 claims description 5
- 238000007796 conventional method Methods 0.000 claims description 4
- 210000002969 egg yolk Anatomy 0.000 claims description 4
- 238000002156 mixing Methods 0.000 claims description 4
- 102000002322 Egg Proteins Human genes 0.000 claims description 3
- 108010000912 Egg Proteins Proteins 0.000 claims description 3
- 238000001035 drying Methods 0.000 claims description 3
- 235000013345 egg yolk Nutrition 0.000 claims description 3
- 239000000284 extract Substances 0.000 claims description 3
- 210000000582 semen Anatomy 0.000 claims description 3
- 238000003556 assay Methods 0.000 claims description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 abstract 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 abstract 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 abstract 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 abstract 1
- 239000003826 tablet Substances 0.000 description 42
- 238000005516 engineering process Methods 0.000 description 13
- 230000037396 body weight Effects 0.000 description 11
- 230000000694 effects Effects 0.000 description 11
- 235000010469 Glycine max Nutrition 0.000 description 10
- 244000068988 Glycine max Species 0.000 description 10
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 10
- 239000012153 distilled water Substances 0.000 description 10
- 238000010521 absorption reaction Methods 0.000 description 9
- 241000700159 Rattus Species 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 8
- 238000000034 method Methods 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 108010023302 HDL Cholesterol Proteins 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 6
- 238000005469 granulation Methods 0.000 description 6
- 230000003179 granulation Effects 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 210000002784 stomach Anatomy 0.000 description 6
- 235000019786 weight gain Nutrition 0.000 description 6
- 229920001479 Hydroxyethyl methyl cellulose Polymers 0.000 description 5
- 235000001727 glucose Nutrition 0.000 description 4
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 4
- 241000255581 Drosophila <fruit fly, genus> Species 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 239000007910 chewable tablet Substances 0.000 description 3
- 229940068682 chewable tablet Drugs 0.000 description 3
- 235000012000 cholesterol Nutrition 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 241000255601 Drosophila melanogaster Species 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 208000031226 Hyperlipidaemia Diseases 0.000 description 2
- 102000007330 LDL Lipoproteins Human genes 0.000 description 2
- 108010007622 LDL Lipoproteins Proteins 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 241000700157 Rattus norvegicus Species 0.000 description 2
- 230000002402 anti-lipaemic effect Effects 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 235000013361 beverage Nutrition 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 235000015111 chews Nutrition 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 229960001031 glucose Drugs 0.000 description 2
- 150000002304 glucoses Chemical class 0.000 description 2
- 239000002932 luster Substances 0.000 description 2
- 238000012946 outsourcing Methods 0.000 description 2
- 238000012856 packing Methods 0.000 description 2
- 230000035515 penetration Effects 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000000630 rising effect Effects 0.000 description 2
- 238000013112 stability test Methods 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- 239000000052 vinegar Substances 0.000 description 2
- 235000021419 vinegar Nutrition 0.000 description 2
- XFZJEEAOWLFHDH-UHFFFAOYSA-N (2R,2'R,3R,3'R,4R)-3,3',4',5,7-Pentahydroxyflavan(48)-3,3',4',5,7-pentahydroxyflavan Natural products C=12OC(C=3C=C(O)C(O)=CC=3)C(O)CC2=C(O)C=C(O)C=1C(C1=C(O)C=C(O)C=C1O1)C(O)C1C1=CC=C(O)C(O)=C1 XFZJEEAOWLFHDH-UHFFFAOYSA-N 0.000 description 1
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 235000011201 Ginkgo Nutrition 0.000 description 1
- 235000008100 Ginkgo biloba Nutrition 0.000 description 1
- 244000194101 Ginkgo biloba Species 0.000 description 1
- DCXXMTOCNZCJGO-UHFFFAOYSA-N Glycerol trioctadecanoate Natural products CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 description 1
- 108010010234 HDL Lipoproteins Proteins 0.000 description 1
- 102000015779 HDL Lipoproteins Human genes 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- CWEZAWNPTYBADX-UHFFFAOYSA-N Procyanidin Natural products OC1C(OC2C(O)C(Oc3c2c(O)cc(O)c3C4C(O)C(Oc5cc(O)cc(O)c45)c6ccc(O)c(O)c6)c7ccc(O)c(O)c7)c8c(O)cc(O)cc8OC1c9ccc(O)c(O)c9 CWEZAWNPTYBADX-UHFFFAOYSA-N 0.000 description 1
- MOJZMWJRUKIQGL-FWCKPOPSSA-N Procyanidin C2 Natural products O[C@@H]1[C@@H](c2cc(O)c(O)cc2)Oc2c([C@H]3[C@H](O)[C@@H](c4cc(O)c(O)cc4)Oc4c3c(O)cc(O)c4)c(O)cc(O)c2[C@@H]1c1c(O)cc(O)c2c1O[C@@H]([C@H](O)C2)c1cc(O)c(O)cc1 MOJZMWJRUKIQGL-FWCKPOPSSA-N 0.000 description 1
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000004958 brain cell Anatomy 0.000 description 1
- 229960001714 calcium phosphate Drugs 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 238000000748 compression moulding Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000037149 energy metabolism Effects 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 229930003944 flavone Natural products 0.000 description 1
- 150000002212 flavone derivatives Chemical class 0.000 description 1
- 235000011949 flavones Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 238000009650 gentamicin protection assay Methods 0.000 description 1
- 239000007952 growth promoter Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000002064 heart cell Anatomy 0.000 description 1
- 230000002443 hepatoprotective effect Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 150000002596 lactones Chemical class 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 239000002075 main ingredient Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 230000008557 oxygen metabolism Effects 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- HGVVOUNEGQIPMS-UHFFFAOYSA-N procyanidin Chemical compound O1C2=CC(O)=CC(O)=C2C(O)C(O)C1(C=1C=C(O)C(O)=CC=1)OC1CC2=C(O)C=C(O)C=C2OC1C1=CC=C(O)C(O)=C1 HGVVOUNEGQIPMS-UHFFFAOYSA-N 0.000 description 1
- 229920002414 procyanidin Polymers 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 230000035806 respiratory chain Effects 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 229930193551 sterin Natural products 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
Abstract
A health-care food for delaying senility and regulating blood fat is prepared from lecithin, VE and the excipient prepared from calcium carbonate, calcium phosphate, cane sugar powder, lactose powder, sorbitol, gelatin, micropowdered silica gel, magnesium stearate and hydroxypropyl methylcellulose.
Description
Technical field
The present invention relates to a kind of health food, specifically relate to a kind of tablet that contains lecithin, has the lecithin efficacy effect, the invention still further relates to this production of health food method.
Background technology
Lecithin (Lecithin) is meant the phospholipid mixture that extracts from Semen sojae atricolor or egg yolk, its Main Ingredients and Appearance comprises cholinphospholipide, cholamine phospholipid, lipositol and phosphoric acid and triglyceride etc.Lecithin in human body, can not only suppress triglyceride synthetic, can also high density lipoprotein increasing, reduce low density lipoprotein, LDL and cholesterol, so the blood lipid regulation effect is arranged.Secondly too high when the human body serum lipid concentrations, the demand of oxygen and energy metabolism level improve, and make respiratory chain produce O
2 -Probability increase, cause the speed of cell peroxidating operation to increase, lecithin alleviates peroxidating by blood fat reducing content on the one hand, can effectively improve SOD level in the cell on the other hand, remove free radical, reduce lipofuscin content, the ability that improves body antagonism peroxide injury reaches the effect of slow down aging.In addition, lecithin also has hepatoprotective, improves nervous tissue, improves the brain vigor, and the prevention cardiovascular and cerebrovascular disease is regulated immunity, promotes effects such as infant brain growth promoter.
Because lecithin is the lipoids material, present lecithin product is made soft capsule with it after with the vegetable oil dilution mostly and since lecithin day dose bigger, people have in fact also taken more vegetable oil when replenishing lecithin.
CN1451313A discloses the health food that contains lecithin and purification vinegar; CN1217383A discloses a kind of health-care wine of soybean lecithinum and manufacture method thereof; CN1194299A discloses lecithin wine; CN1194116A then discloses the lecithin health beverage; CN1203084A also discloses phospholipid tonic paste, and these contain vinegar, wine, the beverage of lecithin or paste up, and are liquid preparation, and the one, lecithin is less stable in liquid preparation, and the 2nd, product is edible and carry all inconvenient.
CN1480146A discloses a kind of preparation and production technology thereof of energy blood lipid regulation blood pressure and blood sugar protection heart and brain cell, and this is invented ginkgo flavone and lactone, soybean lecithin, procyanidin, mixes in proportion; add ethanol; make soft material, with granulation machine sieve granule, wet grain drying sterilization; granulate; under aseptic condition, add lubricant, mix homogeneously; encapsulated, get product after the sealing packing.CN1102550A discloses special effetive healthy lecithin series foods, and this invention is a main body with lecithin and fatty acid mixt, adds appropriate amount of auxiliary materials, makes capsule.Because every capsules loading amount is limited, also contains more other composition or adjuvant in the said goods except that lecithin, in the time of reaching effective dose, the dose of capsule product is just quite big.
So someone makes granule with lecithin, though graininess lecithin can overcome the some shortcomings of the said goods, the surface area that the lecithin granule contacts with air is big, and is easily oxidized and produce spoiled and bad mouthfeel.
In sum, yet there are no and can keep lecithin peculiar flavour and biological effect, can keep its physicochemical property stable again, use and carry all very convenient, the product form that consumer takes like a shot.
Summary of the invention
Order of the present invention is to overcome above-mentioned the deficiencies in the prior art, provide a kind of and contained lecithin, had the slow down aging of lecithin efficacy effect and health food, the particularly tablet of blood lipid regulation, the unilateral outsourcing last layer of this tablet film-coat, can stop air and moisture penetration effectively, keep the stable of lecithin physicochemical property.Secondly, the excipient compatibility is selected rationally to be easy to the industrial mass compression molding, and production cost is lower.
Another object of the present invention has provided this health food, particularly contains the production technology of lecithin chewable tablet.
The present invention can be achieved through the following technical solutions:
The health food of a kind of slow down aging and blood lipid regulation is the tablet of being made by following part of raw material: lecithin 40-500 part, excipient 400-850 part.
The health food of a kind of slow down aging and blood lipid regulation is the tablet of being made by following part of raw material: lecithin 100-400 part, excipient 500-700 part.
The health food of a kind of slow down aging and blood lipid regulation is the tablet of being made by following part raw material: lecithin 40-500 part, vitamin E2-50 part, excipient 400-850 part.
The health food of a kind of slow down aging and blood lipid regulation, excipient are a class or the number class in binding agent, filler, fluidizer, lubricant, the coating materials.
The health food of a kind of slow down aging and blood lipid regulation, excipient is made by following part of raw material: binding agent is a general tablet binding agent commonly used, gelatin, the filler that is preferably 2-10 part is general tablet filler commonly used, is preferably calcium carbonate of 50-400 part or the calcium phosphate of 0-90 part or the micropowder silica gel that the two share, fluidizer is 10-30 part, magnesium stearate, the coating materials that lubricant is 15-30 part is the hydroxypropyl emthylcellulose of 10-30 part.
The health food of a kind of slow down aging and blood lipid regulation, the lecithin 50-500 part that comprises weight proportion, vitamin E 5-50 part, used excipient is made up of the materials of weight proportions of following one or more combinations: calcium carbonate 50-400 part, calcium phosphate 0-90 part, cane sugar powder 0-750 part, lactose powder 0-300 part, Sorbitol 0-300 part, gelatin 0-10 part, micropowder silica gel 10-30 part, magnesium stearate 15-30 part, hydroxypropyl emthylcellulose 10-30 part.
The health food of a kind of slow down aging and blood lipid regulation comprises that 20 parts of 20 parts of 10 parts in 550 parts of 160 parts of 0 part of 200 parts in lecithin, vitamin E2, calcium carbonate, cane sugar powders, gelatin, micropowder silica gels, magnesium stearate, the hydroxypropyl emthylcellulose of weight proportion made for 20 parts.
The health food of a kind of slow down aging and blood lipid regulation, the more suitably product form of described tablet is the masticatory pattern tablet.
The health food of a kind of slow down aging and blood lipid regulation, the used lecithin of product are the phospholipid mixture that extracts from Semen sojae atricolor or egg yolk with conventional method.
The production of health food of a kind of slow down aging and blood lipid regulation, make by the poly-operation of following step: get soybean lecithin, vitamin E, calcium carbonate, cane sugar powder mixing in proportion and be broken for powder, the suitable quantity of water that adds 1-5 times is made soft material, 14 mesh sieves obtain wet granular excessively, 65 ℃ of oven dry after 16 mesh sieve granulate, add micropowder silica gel, magnesium stearate, mixing, the tablet machine tabletting, plain sheet, gets product after the drying with hydroxypropyl emthylcellulose coating material coating through after the assay was approved.
The health food that provides of the present invention carries out animal experiment and human trial according to the functional assessment process of health food, and method and result are summarized as follows:
Slow down aging test method and result
Detect by OregonK wild type Drosophila melanogaster (Drosophila melanogaster) survival assay and SPF level Kunming kind female mice biochemical indicator, the conclusion that obtains is: sample tablet 0.03%, 0.09%, 0.27%, 0.80% dosage group can obviously prolong the average life of male drosophila, with the matched group comparing difference significance is arranged, P＜0.01, P＜0.01, P＜0.01, P＜0.01.0.09%, 0.27%, 0.80% dosage group can obviously prolong the average life of female fruit bat, with the matched group comparing difference significance is arranged, P＜0.01, P＜0.01, P＜0.01.0.09%, 0.27%, 0.80% dosage group can obviously prolong maximum life span female, male drosophila, than difference significance is arranged compared with the control, P＜0.01, P＜0.01, P＜0.01.0.03%, 0.09%, 0.27%, 0.80% dosage group male drosophila half death time is respectively greater than matched group 7 days, 4 days, 5 days, 4 days.0.09%, the female fruit bat half death time of 0.27%, 0.80% dosage group is respectively greater than matched group 10 days, 10 days, 8 days.Recommend 5,10,20 times of human body daily intaking amount 8g/60Kg.BW to be equivalent to manufacturer, as basic, normal, high dosage group (corresponding dosage be 0.67,1.33,2.66g/Kg.BW).Adopt SPF level Kunming mouse per os to irritate stomach 1 month, result of the test shows that basic, normal, high dosage group can obviously reduce aged mouse 2% hemolysate MDA content, has significance with aged matched group comparing difference, P＜0.01, P＜0.01, P＜0.01.The middle and high dosage group aged mouse whole blood GSH-PX activity that can obviously raise has significance with aged matched group comparing difference, P＜0.05, P＜0.01.In the dosage group aged mouse erythrocyte sod activity that can obviously raise, significance is arranged, P＜0.05 with aged matched group comparing difference.According to the functional assessment process regulation of health food, of the present invention this tried thing delaying senility function.
Blood lipid regulation test method and result:
Material and method:
Sample source and processing: chewable tablet is a white powder, directly gets to be tried thing and be mixed with the suspension of required variable concentrations with distilled water, is provided with down test and uses.
Laboratory animal: SPF level Wistar rat, body weight 140-160g, male, totally 50.Experimental temperature: 22-24 ℃, relative humidity: 65-80%.
Feedstuff: common basic feedstuff.High lipid food: 78.8% common normal feedstuff, 10% yolk powder, 10% lard stearin, 1% cholesterol.The dosage grouping: experiment is divided into five groups, every group of 10 animals.Normal control group, model control group and basic, normal, high dosage group are set.The normal control group gives common normal feedstuff, irritates stomach with distilled water; Model control group and basic, normal, high dosage group give high lipid food, and irritate stomach with the chewable tablet distilled water preparation liquid per os of distilled water and 0.67,1.33,2.66/kg.BW dosage respectively; Basic, normal, high dosage group is equivalent to 5,10,20 times of the recommendation human intaking amount of manufacturer (8.0g/60kg.BW) respectively.
Experimental technique:
The rat adaptability is raised and is begun experiment after 3 days.Get rat tail blood, detect serum total cholesterol (TC), triglyceride (TC), HDL-C (HDL-C).According to the TC level, rat is divided into normal control group (10) and hyperlipidemia model group (totally 40) at random.The normal control group gives common normal feedstuff, and all the other are respectively organized and give high lipid food, and basic, normal, high dosage group is also irritated stomach simultaneously and is subjected to thing on probation, gives 28 days continuously in irritating stomach detection in the 29th day TC, TG, HDL-C value.
Key instrument and reagent: SABA-18 type automatic clinical chemistry analyzer, standard quality controlled serum and corresponding reagent box are produced by biological engineering High-tech company in Beijing.
The result:
Tried the influence of thing to the hyperlipidemia model the weight of animals: compare with model control group, basic, normal, high dosage group body weight difference does not have significance, and normal control group rat body weight all around the time is starkly lower than model control group, and difference has significance, P＜0.005.
Tried the influence of thing to rat HDL-C content: as seen from Table 1, compare with model control group, each dosage group does not all have obvious rising effect to the height protein cholesterol during off-test.
Table 1 tried thing to the influence of rat high density fat sterin content (mmol/L, xs)
| Group | Dosage (g/kg.BW) | Animal only | HDL-C | |
| Before the experiment | After the experiment | |||
| Dosage group high dose group in the normal control model contrast low dose group | ??0 ??0 ??0.67 ??1.33 ??2.66 | ??10 ??10 ??10 ??10 ??10 | ??0.99±0.17 ??1.04±0.14 ??1.08±0.07 ??1.05±0.09 ??1.05±0.13 | ??0.98±0.18 ??1.41±0.15 ??1.47±0.22 ??1.45±0.15 ??1.48±0.19 |
* compare P＜0.05 with model control group
Brief summary:
Auxiliary antilipemic adopts the disorderly modelling of prevention type lipid metabolism in rats, recommend 5,10,20 times of human body daily intaking amount (0.8g/60kgBW) to be equivalent to manufacturer, as basic, normal, high dosage group (corresponding actual dose is 0.671.332.66g/kg.BW).Adopt SPF level Wistar rat oral to irritate stomach, the result shows: 1, with model control group relatively, basic, normal, high dosage group body weight difference does not have significance, the normal control group around the time rat body weight be starkly lower than model control group, difference has significance, P＜0.05.2, model control group compares, and low, middle dosage group total cholesterol level descended obviously when experiment finished, and credit is analysed by statistics, difference has significance, P＜0.05, P＜0.05, and the low dose group content of triglyceride descends obviously, credit is analysed by statistics, and difference has significance, P＜0.05.Each dosage group does not all have obvious rising effect to HDL-C.According to health food function assessment assessment process regulation, this is tried thing the auxiliary antilipemic effect.
The invention has the advantages that provides a kind of tablet that contains lecithin, has the lecithin efficacy effect, the surface area that contacts with air dwindles greatly, unilateral outsourcing last layer film-coat can stop air and moisture penetration effectively, keeps the stable of lecithin physicochemical property.Secondly, the tablet packing is carried and is used all quite conveniently, and industrial mass tabletting, production cost are also low.The 3rd, this sheet designs by rational formula, and the product mouthfeel is fine, chews clothes in mouthful and the time can produce lecithin special delicate fragrance flavor, and the eater takes like a shot very much, also chews because of tablet and makes the easier absorption of lecithin after thin.The 4th, product proves to have the action and efficacy of tangible slow down aging and blood lipid regulation by animal experiment and human feeding trial.
The present invention is further elaborated below in conjunction with embodiment, but therefore the present invention is not construed as limiting.
The specific embodiment
Embodiment 1:
200 parts of soybean lecithins, 0 part of vitamin E2,120 parts of calcium carbonate, 600 parts of cane sugar powders, 20 parts of micropowder silica gels, 20 parts of magnesium stearate, 20 parts of hydroxypropyl emthylcelluloses.
Production technology: get raw material mix homogeneously such as soybean lecithin, vitamin E, calcium carbonate, cane sugar powder in proportion, the an amount of distilled water that adds 3 times is made soft material, is crossed the granulation of 14 mesh sieves, 65 ℃ of oven dry, 16 mesh sieve granulate, adding micropowder silica gel, magnesium stearate are mixed, 21 towards rotary tablet machine be pressed into every sheet heavily be 0.98 the gram plain sheet, the more plain coating tablets that will be pressed into the hydroxypropyl emthylcellulose coating material make every sheet heavily increase to 1 the gram, get product.
Embodiment 2:
50 parts of soybean lecithins, 5 parts of vitamin Es, 50 parts of calcium carbonate, 65 parts in calcium phosphate, 145 parts of cane sugar powders, 200 parts in lactose powder, 10 parts of micropowder silica gels, 15 parts of magnesium stearate, 10 parts of hydroxypropyl emthylcelluloses, production technology: get soybean lecithin in proportion, vitamin E, calcium carbonate, calcium phosphate, cane sugar powder, raw material mix homogeneously such as lactose powder, an amount of distilled water that adds 1 times is made soft material, crossing 14 mesh sieves granulates, 65 ℃ of oven dry, 16 mesh sieve granulate add micropowder silica gel, magnesium stearate is mixed, and 21 are pressed into towards rotary tablet machine, every sheet heavily is controlled to be 0.485 gram, and the finished product sheet heavily is every 0.5 gram behind the coating.
Embodiment 3:
500 parts of soybean lecithins, 50 parts of vitamin Es, 400 parts of calcium carbonate, 300 parts in lactose powder, 50 parts of cane sugar powders, 30 parts of micropowder silica gels, 30 parts of magnesium stearate, 30 parts of hydroxypropyl emthylcelluloses.Production technology: get raw material mix homogeneously such as soybean lecithin, vitamin E, calcium carbonate, cane sugar powder, lactose powder in proportion, the an amount of distilled water that adds 5 times is made soft material, is crossed the granulation of 14 mesh sieves, 65 ℃ of oven dry, 16 mesh sieve granulate, adding micropowder silica gel, magnesium stearate are mixed, 21 are pressed into towards rotary tablet machine, and every sheet heavily is controlled to be 0.98 gram, and the finished product sheet heavily be every 1 and restrains behind the coating.
Embodiment 4:
200 parts of soybean lecithins, 0 part of vitamin E2,120 parts of calcium carbonate, 90 parts in calcium phosphate, 300 parts of sorbitol, 300 parts of cane sugar powders, 20 parts of micropowder silica gels, 20 parts of magnesium stearate, 25 parts of hydroxypropyl emthylcelluloses.Production technology: identical with embodiment 1.
Embodiment 5:
200 parts of soybean lecithins, 20 parts of vitamin Es, 120 parts of calcium carbonate, 300 parts of sorbitol, 750 parts of cane sugar powders, 5 parts in gelatin, 20 parts of micropowder silica gels, 20 parts of magnesium stearate, 25 parts of hydroxypropyl emthylcelluloses.Production technology: identical with embodiment 1.
Embodiment 6:
200 parts of soybean lecithins, 0 part of vitamin E2,120 parts of calcium carbonate, 200 parts of sorbitol, 100 parts of cane sugar powders, 200 parts in lactose powder, 10 parts in gelatin, 20 parts of micropowder silica gels, 20 parts of magnesium stearate, 25 parts of hydroxypropyl emthylcelluloses.Production technology: identical with embodiment 1.
Finished product sheet weight average behind above embodiment 1,3,4,5, the 6 gained coatings is an every 0.97-1.02 gram, and does not have sticking, hangs and dashes, and the sliver phenomenon is fit to be applied to commercial production.Hydroxypropyl emthylcellulose is a coating material.
Embodiment 7:
200 parts of soybean lecithins, 0 part of vitamin E2,740 parts of glucoses, 20 parts of magnesium stearate.
Production technology:
Get soybean lecithin, vitamin E, glucose powder mix homogeneously in proportion, adding an amount of distilled water makes soft material, crosses the granulation of 14 mesh sieves, 65 ℃ of oven dry, 16 mesh sieve granulate, adding magnesium stearate is mixed, occur sticking during tabletting, hang and dash, sliver, and tablet weight variation is big, every sheet is reconstructed and is controlled to be 0.98 gram, but in 1000 finished products, has 135 sheets great in 1.10 grams, there are 45 sheets heavy less than 0.90 gram, explanation contains the lecithin tablet by general conventional method preparation, and it is more to go wrong, and is difficult to be applied to commercial production.
Embodiment 8:
200 parts of soybean lecithins, 0 part of vitamin E2,300 parts of glucoses, 200 parts in lactose powder, 20 parts of micropowder silica gels, 20 parts of magnesium stearate.
Production technology:
Get soybean lecithin, vitamin E, glucose powder, lactose powder mix homogeneously in proportion, adding an amount of distilled water makes soft material, crosses the granulation of 14 mesh sieves, 65 ℃ of oven dry, 16 mesh sieve granulate, adding micropowder silica gel, magnesium stearate are mixed, occur sticking during tabletting, hang and dash, sliver, and tablet weight variation is big, every sheet is reconstructed and is controlled to be 0.98 gram, but in 1000 finished products, has 56 sheets great in 1.10 grams, there are 34 sheets heavy less than 0.90 gram, explanation contains the lecithin tablet by general conventional method preparation, and it is more to go wrong, and is difficult to be applied to commercial production.
Embodiment 9:
The plain sheet of embodiment 1 gained is reserved a part compare, other gets a part of hydroxypropyl emthylcellulose coated tablet in same storage requirement, carries out stability test, found that the coated tablet hygroscopicity is little.Moisture absorption tablet too, unilateral color and luster deepens, the obvious variation of mouthfeel, tablet hardness descends, and illustrates that plain coating tablets has tangible effect to improving the lecithin physical and chemical stability.See table 2 for details
Table 2: embodiment 1 plain sheet and hydroxypropyl emthylcellulose coated tablet moisture absorption rate of body weight gain are relatively
| Plain sheet moisture absorption rate of body weight gain % | Coated tablet moisture absorption rate of body weight gain % | |||
| 0 day | 30 days | 0 day | 30 days | |
| Room temperature is placed test | ??--- | ??0.85 | ?--- | ??0.15 |
| Constant temperature and humidity accelerated test (70% relative humidity, 37 ℃) | ??--- | ??3.45 | ?--- | ??0.48 |
Embodiment 10:
200 parts of soybean lecithins, 0 part of vitamin E2,120 parts of calcium carbonate, 600 parts of cane sugar powders, 20 parts of micropowder silica gels, 20 parts of magnesium stearate, 20 parts of methyl hydroxyethylcelluloses.
Production technology: get raw material mix homogeneously such as soybean lecithin, vitamin E, calcium carbonate, cane sugar powder in proportion, the an amount of distilled water that adds 3 times is made soft material, is crossed the granulation of 14 mesh sieves, 65 ℃ of oven dry, 16 mesh sieve granulate, adding micropowder silica gel, magnesium stearate are mixed, 21 towards rotary tablet machine be pressed into every sheet heavily be 0.98 the gram plain sheet, the more plain coating tablets that will be pressed into the methyl hydroxyethylcellulose coating material make every sheet heavily increase to 1 the gram, get product.
The plain sheet of gained is reserved a part compare, other gets a part of methyl hydroxyethylcellulose coated tablet in same storage requirement, carries out stability test, found that the coated tablet hygroscopicity is little.The tablet that moisture absorption is big, unilateral color and luster deepens, the obvious variation of mouthfeel, tablet hardness descends, and illustrates that plain coating tablets has tangible effect to improving the lecithin physical and chemical stability.See table 3 for details.
Table 3: embodiment 10 plain sheets and methyl hydroxyethylcellulose coated tablet moisture absorption rate of body weight gain are relatively
| Plain sheet moisture absorption rate of body weight gain % | Coated tablet moisture absorption rate of body weight gain % | |||
| 0 day | 30 days | 0 day | 30 days | |
| Room temperature is placed test | ?--- | ?0.85 | ?--- | ?0.23 |
| Constant temperature and humidity accelerated test (70% relative humidity, 37 ℃) | ?--- | ?3.45 | ?--- | ?0.74 |
Be all coated tablet, aspect protection soybean lecithin stability, the hydroxypropyl emthylcellulose coated tablet is than methyl hydroxyethylcellulose coated tablet better effects if.
Claims (10)
1. the health food of slow down aging and blood lipid regulation is characterized in that it being the tablet of being made by following part of raw material: lecithin 40-500 part, excipient 400-850 part.
2. according to the health food of described slow down aging of claim 1 and blood lipid regulation, be the tablet of making by following part of raw material: lecithin 100-400 part, excipient 500-700 part.
3. according to the health food of described slow down aging of claim 1 and blood lipid regulation, it is characterized in that also comprising in the raw material vitamin E 2-50 part.
4. according to the health food of claim 1 or 2 or 3 described slow down aging and blood lipid regulation, it is characterized in that excipient is a class or the number class in binding agent, filler, fluidizer, lubricant, the coating materials.
5. according to the health food of claim 1 or 2 or 3 described slow down aging and blood lipid regulation, it is characterized in that excipient made by following part raw material: binding agent is a general tablet binding agent commonly used, gelatin, the filler that is preferably 2-10 part is general tablet filler commonly used, is preferably calcium carbonate of 50-400 part or the calcium phosphate of 0-90 part or the micropowder silica gel that the two share, fluidizer is 10-30 part, magnesium stearate, the coating materials that lubricant is 15-30 part is the hydroxypropyl emthylcellulose of 10-30 part.
6. according to the health food of described slow down aging of claim 3 and blood lipid regulation, it is characterized in that comprising lecithin 50-500 part of weight proportion, vitamin E 5-50 part, used excipient is made up of the materials of weight proportions of following one or more combinations: calcium carbonate 50-400 part, calcium phosphate 0-90 part, cane sugar powder 0-750 part, lactose powder 0-300 part, Sorbitol 0-300 part, gelatin 0-10 part, micropowder silica gel 10-30 part, magnesium stearate 15-30 part, hydroxypropyl emthylcellulose 10-30 part.
7. according to the health food of claim 1 or 6 described slow down aging and blood lipid regulation, the more suitably product form that it is characterized in that described tablet is the masticatory pattern tablet.
8. according to the health food of claim 1 or 6 described slow down aging and blood lipid regulation, it is characterized in that 20 parts of 20 parts of 10 parts in 550 parts of 160 parts of 20 parts of 200 parts in lecithin, vitamin Es, calcium carbonate, cane sugar powders, gelatin, micropowder silica gels, the magnesium stearate, the hydroxypropyl emthylcellulose that comprise weight proportion make for 20 parts.
9. according to the health food of claim 1 or 6 described slow down aging and blood lipid regulation, it is characterized in that used lecithin is the phospholipid mixture that extracts with conventional method from Semen sojae atricolor or egg yolk.
10. the production of health food of claim 1 or 6 described slow down aging and blood lipid regulation, it is characterized in that making: get soybean lecithin, vitamin E, calcium carbonate, cane sugar powder mixing in proportion and be broken for powder by the poly-operation of following step, the suitable quantity of water that adds 1-5 times is made soft material, 14 mesh sieves obtain wet granular excessively, 65 ℃ of oven dry, after 16 mesh sieve granulate, add micropowder silica gel, magnesium stearate, mixing, the tablet machine tabletting, plain sheet, gets product after the drying with hydroxypropyl emthylcellulose coating material coating through after the assay was approved.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2004100133423A CN100512679C (en) | 2004-06-22 | 2004-06-22 | Health-care food for delaying senility and regulating blood fat and its production |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2004100133423A CN100512679C (en) | 2004-06-22 | 2004-06-22 | Health-care food for delaying senility and regulating blood fat and its production |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1711912A true CN1711912A (en) | 2005-12-28 |
| CN100512679C CN100512679C (en) | 2009-07-15 |
Family
ID=35717836
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2004100133423A Expired - Lifetime CN100512679C (en) | 2004-06-22 | 2004-06-22 | Health-care food for delaying senility and regulating blood fat and its production |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN100512679C (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101156862B (en) * | 2007-09-29 | 2010-06-23 | 北京世纪博康医药科技有限公司 | A lecithin vitamine E mastication piece and method for making same |
-
2004
- 2004-06-22 CN CNB2004100133423A patent/CN100512679C/en not_active Expired - Lifetime
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101156862B (en) * | 2007-09-29 | 2010-06-23 | 北京世纪博康医药科技有限公司 | A lecithin vitamine E mastication piece and method for making same |
Also Published As
| Publication number | Publication date |
|---|---|
| CN100512679C (en) | 2009-07-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102283386B (en) | Composite camellia oil health care product with function of reducing blood fat and preparation method thereof | |
| CN1917894A (en) | Muscular tension-elevating agent | |
| JP4580034B2 (en) | Calcium ion sustained release agent | |
| CN110074191A (en) | A kind of nutrition chewing milk tablet and preparation method thereof for adding DHA algal oil microcapsule powder | |
| CN1927050A (en) | DHA microcapsule food additives, DHA soft capsule health product and uses thereof | |
| CN1714655A (en) | Ginkgo biscuit, rice biscuit and its producing method | |
| CN108888601A (en) | A kind of vitamin E selenium microcapsules tablet, preparation method and its usage | |
| CN109645195A (en) | A kind of DHA algal oil phosphatidylserine pressed candy and preparation method thereof | |
| CN106036898A (en) | Composition having anti-fatigue effects and preparation method and use thereof | |
| CN1270624C (en) | Pollen, bee milk food and its preparation method | |
| CN1911089A (en) | Food prepns. by using vegetables and/or fruits as raw material and its prepn. method | |
| CN1205880C (en) | Health-care food with immune-regulating and face-beautifying function and its preparation method | |
| CN1711912A (en) | Health-care food for delaying senility and regulating blood fat, and its production | |
| CN1253159C (en) | Health product of compound propolis and preparing method | |
| CN1394116A (en) | Use of cereal product for improving cognitive performance and mental well-being in a person, particularly in child and adolescent | |
| CN1685918A (en) | Portable honey stuffing life nourishing food and its special processing equipment | |
| CN110150678A (en) | Ginseng dietary fiber chewable tablets and preparation method thereof | |
| CN102028222A (en) | Soya bean lecithin chewable tablets | |
| CN1283269C (en) | Compound preparation of forest frog, and preparation method | |
| CN1768035A (en) | Anti-obesity agent | |
| CN1437883A (en) | Chewing tablet of edible tree fungi and calcium and making process | |
| CN110463904A (en) | A kind of wheat bran compound nutritional chewable tablets and its processing method | |
| CN1966069A (en) | Application of edestin in preparation of functional food for relieving anemia | |
| CN1939344A (en) | Donkey-hide gelatin oral preparation and its making method | |
| CN1209978C (en) | Nutritive health-care food for supplementing nucleic acid and its preparing process |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CX01 | Expiry of patent term |
Granted publication date: 20090715 |
|
| CX01 | Expiry of patent term |